Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Laura A. Carleton, Laura Breen, Aidan P. Toner, Sharon A. Glynn, Francis J. Giles, Joe Lewis, F McLaughlin, Francis J. Sullivan, Adrienne M. Gorman, G Dunne, Enda O'Connell
Publikováno v:
British Journal of Cancer
Background: Taxanes are routinely used for the treatment of prostate cancer, however the majority of patients eventually develop resistance. We investigated the potential efficacy of EL102, a novel toluidine sulphonamide, in pre-clinical models of pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b0d73b25d4798f080df4b61b3dce051
http://hdl.handle.net/10379/14177
http://hdl.handle.net/10379/14177
Autor:
Tamotsu Sagawa, Kan Yonemori, Kenji Tamura, Makoto Kodaira, Fumihiko Hirai, Toshio Kawata, Ben Hatano, Yuki Yokoi, Koshi Fujikawa, Yasuo Takahashi, Tsuyoshi Shirakawa, Taito Esaki
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic p
Publikováno v:
Investigational New Drugs
Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This Phase I study (clinicaltrials.gov identifier: NCT00326950) was
Autor:
Minami Matsuda, Keishi Yamashita, Keisuke Miwa, Yasutsuna Sasaki, Namiki Masayuki, Ken Shimada, Kosei Hasegawa, Hiroo Ishida, Keiichi Fujiwara, Yutaka Takeuchi, Yasuhiro Fujiwara, Noriyuki Katsumata, Makoto Kodaira, Yu Sunakawa
Publikováno v:
Investigational New Drugs
SummaryFarletuzumab is a humanized monoclonal antibody against folate receptor α (FRA). The purpose of the study is to assess safety and tolerability, the pharmacokinetic (PK) profile, and preliminary antitumor effect. Patients with ovarian cancer (
Autor:
Ayako Tsuchiya, Akito Tanaka, Tadashi Shimizu, Shuhei Nakao, Tomoyuki Nishizaki, Yoshiko Kaku, Takeshi Kanno
Publikováno v:
Cancer Chemotherapy and Pharmacology
Naftopidil is clinically for treatment of benign prostate hyperplasia, and emerging evidence has pointed to its anticancer effect. To obtain the anticancer drug with the potential greater than that of naftopidil, we have newly synthesized the naftopi
Autor:
Peter Stopfer, Rolf Kaiser, Martin Büchert, Matus Studeny, Klaus Mross, Michael Medinger, A. Frost
Publikováno v:
BMC Cancer
Background Nintedanib is a potent, oral angiokinase inhibitor that targets VEGF, PDGF and FGF signalling, as well as RET and Flt3. The maximum tolerated dose of nintedanib was evaluated in a phase I study of treatment-refractory patients with advance
Autor:
Annalisa La Cesa, Angelo Vincenzi, Daniele Santini, Simona Gasparro, Gaia Schiavon, Giuseppe Tonini, Bruno Vincenzi
Publikováno v:
BMC Cancer, Vol 6, Iss 1, p 42 (2006)
BMC Cancer
BMC Cancer
Background The combination of capecitabine and gemcitabine at Fixed Dose Rate (FDR) has been demonstrated to be well tolerated, with apparent efficacy in patients with advanced cancers. FDR gemcitabine infusion leads to enhanced intracellular accumul
Publikováno v:
BMC Cancer
Background Albendazole (ABZ) is a microtubule-targeting anthelmintic with a remarkable activity against a variety of human cancer cells. In this study, we examined if the antitumor activity of ABZ could be enhanced by its combination with other micro
Autor:
Richard Isaacs, David Perez, Michael Findlay, Katrina Sharples, Christopher Jackson, Victoria Hinder, J.D. Adams, Sanjeev Deva, Anne O'Donnell, Paul Thompson, Bridget A. Robinson
Publikováno v:
BMC Cancer
Background Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorect
Autor:
P. Gatti, Giulia Bertino, F. Zappoli, Franco Corbella, Eugenio Mira, Carmine Tinelli, Marco Benazzo, Gianni Bernardo
Publikováno v:
BMC Cancer
BMC Cancer, Vol 7, Iss 1, p 62 (2007)
BMC Cancer, Vol 7, Iss 1, p 62 (2007)
Background This study evaluated the feasibility, toxicity, response rate and survival of neoadjuvant superselective intra-arterial infusion of high dose carboplatin in advanced head and neck cancer. Methods Forty-six patients with primary head and ne